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Cardio-Oncology for the 21st Century: Introduction 
 
Based on the latest statistics the prognosis for patients with malignancy has 
dramatically improved. The overall 5 year survival rate for those who were 
diagnosed with a cancer between 2002 and 2008 was approximately 65%1, and as 
of 2008, 12 million Americans were cancer survivors.2 However, this extended 
longevity now exposes these patients to the risk of other health issues related to 
their primary cancer or to the treatment that ensured their survival. Specifically, 
patients who have not succumbed prematurely to their oncologic disease may 
develop cardiovascular disease that is either a result of the long-term effects of their 
traditional cardiovascular risk factors or that is due to the direct cardiovascular 
toxicity of the cancer itself or from the administered therapy. In fact, Patnaik and 
colleagues reviewed the Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked database and found that breast cancer survivors were as likely to 
die from cardiovascular disease as from recurrent breast cancer.3 Additionally, 
Mertens and colleagues found that cardiovascular events are the leading cause of 
nonmalignant deaths in survivors of childhood cancers.4 
 Because of the ongoing need for recurrent cancer monitoring, the treating 
oncologist may be the de facto primary care physician for many oncologic patients.  
Also, the treating oncologist is the most knowledgeable physician with regard to the 
possible toxicities related to a patient’s cancer and any administered therapy. 
Therefore, in addition to monitoring these patients for recurrent oncologic disease, 
it is the treating oncologist’s responsibility to be cognizant of other long-term health 
complications to which these patients are susceptible. This special edition of 
Seminars in Oncology reviews the cardiovascular issues that can arise during the 
ongoing care of oncologic patients.  
 
Cardiovascular disease assessment begins with a careful history that includes 
questions about the presence of symptoms that may not be part of the usual review 
of systems associated with cancer patients. A change in exercise tolerance either 
due to chest/neck/shoulder discomfort or dyspnea, complaints of near- syncope or 
syncope, feelings of rapid or irregular palpitations, or an awareness of peripheral 
edema or pulmonary congestion may be indicators of cardiac decompensation. 
Additionally, in order to complete the cardiovascular history, the presence of known 
risk factorshypertension, hyperlipidemia, diabetes, physical inactivity, significant 
family history, and tobacco/alcohol usageshould be assessed.  
 
During a cancer patient’s physical examination, the oncologist needs to include a 
careful evaluation of the cardiovascular system, including the measurement of 
accurate vital signs (blood pressure should be obtained with the arm held at heart 
level while the patient is sitting on a chair, feet on the floor, after 5 minutes of 
relaxation5), assessment of the jugular venous pressure, auscultation for the 
presence of arterial bruits as well as for cardiac murmurs, gallops, and rubs, and 
observation for signs of hypervolemia (e.g., pulmonary congestion, edema, ascites, 
hepatic congestion).   
 
Based on this history and physical examination, a cancer patient may require 
further cardiac tests such as electrocardiograms, echocardiograms, nuclear imaging 
scans, and biomarker measurements. Depending upon the level of the patient’s risk 
and the complexity of the issues involved, co-evaluation with a cardiologist familiar 
with these cardio-oncologic issues may be appropriate. Davis and Witteles review 
strategies for cardiac testing in cancer patients at high risk of cardiac complications. 
In order to assess and treat the long-term risk of developing cardiac disease in 
cancer survivors, Carver et al propose a comprehensive diagnostic and therapeutic 
strategy. 
 
Although cardiovascular toxicity including left ventricular systolic dysfunction, 
heart failure, hypertension, coronary ischemia, pericardial disease, and arrhythmias 
may develop from all of the classes of cancer therapy, a variety of cancers 
themselves may adversely affect the cardiovascular system as well. Bonita and 
Pradhan review the possible toxicities of the chemotherapeutic agents, while Ryberg 
discusses the cardiac concerns related to treatment with the biologic agents. The 
cardiotoxic effects of radiation therapy are discussed by Martinou and Gaya. 
Regarding cancer-induced cardiac toxicity, Lenihan et al review the evaluation and 
management of infiltrative cardiomyopathies and pericardial disease. 
 
Rather than only identifying patients who may have developed overt cardiac toxicity 
from their cancer-related disease, the ultimate goal for both the oncologist and the 
cardiologist is to prevent the development of these complications. Cardinale et al 
review the literature with regard to promising strategies in this area and share the 
available data regarding treatment options. 
 
In addition to the insults that occur to the cardiovascular system as a result of a 
patient’s cancer or their cancer treatment, a patient’s oncologic status may also be 
affected by their preexisting cardiovascular disease. Many cancer patients will 
already be maintained on the kind of complex cardiovascular drug regimen that has 
led to improved survival among cardiac patients. Chen and Parameswaran review 
how these cardiac agents will affect a cancer patient’s clinical status and therapeutic 
treatment options.  
 
Given the interplay between oncologic and cardiac disease states, Jones et al explore 
the risk factors common to both of these conditions and demonstrate the data that 
support a preventive treatment strategy, including exercise, that might be effective 
in decreasing the incidence of both cancer and cardiac disease. 
 
In an era when more effective detection and treatment of both oncologic and 
cardiovascular disease states are available, it is incumbent upon treating physicians 
to be aware of the complicating issues that may negatively impact the prognosis of 
these patients. More outcomes data is needed to guide specific care 
recommendations, but in the meantime, close consultation between oncologists and 
cardiologists is required for the optimal management of patients who have, or who 
are at risk for developing, cardio-oncologic disease.   
   
 
 
References 
 
1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al 
(eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), 
National Cancer Institute. Bethesda MD, 
http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 
SEER data submission, posted to the SEER web site, April 2012. 
2. Am Cancer Society. Cancer Facts and Figures. 2012 Atlanta: American Cancer 
Society;2012. 
3. Patnaik JL, Byers T, Di Guiseppi C, Dabelea D, Denberg TD. Cardiovascular 
disease competes with breast cancer as the leading cause of death for older 
females diagnosed with breast cancer: a retrospective cohort study. Breast 
Cancer Res. 2011;13:R64. 
4. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. 
Cause –specific late mortality among 5-year survivors of childhood cancer: 
the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100(19):1368-
79. 
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. 
7th Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure: the JNC 7report. JAMA 
2003May21;289:2560-72. 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
